Novocure to Present NovoTTF™ Therapy Data at the 2013 Annual Scientific Meeting of the American Society of Clinical Oncology

May 31, 2013, 09:00 ET from Novocure

PORTSMOUTH, N.H., May 31, 2013 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today that data from pre-clinical and clinical studies evaluating NovoTTF™ Therapy will be presented and published online as part of the 49th Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, May 31-June 4, 2013.

The clinical data includes a detailed analysis of time to tumor progression for patients with recurrent glioblastoma treated with NovoTTF Therapy compared to patients treated with chemotherapy and a safety analysis of bevacizumab plus NovoTTF Therapy in patients with recurrent malignant gliomas.

Several pre-clinical and experimental data updates will also be published in conjunction with ASCO 2013 and can be found online at

About Glioblastoma

Glioblastoma (GBM) is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year. Historically, based on literature, the median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the deadliest forms of cancer.

About the NovoTTF™-100A System

NovoTTF™-100A System is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in both in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy. The NovoTTF-100A has received marketing approval in the US and is a CE Marked device that is cleared for sale in Europe.

Approved Indication

The US Food and Drug Administration (FDA) has approved the NovoTTF™-100A System for use as a treatment for adult patients (22 years of age or older) with histologically confirmed glioblastoma multiforme (GBM), following histologically – or radiologically confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device. Full prescribing information is available at or by calling toll free 1-855-281-9301.

About Novocure™ Limited and Novocure Inc. 

Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors. Novocure's US subsidiary, Novocure Inc., has operations based in New York, NY and Portsmouth, NH. For additional information about the company, please visit

Media contact: 
Peter Melnyk
(212) 767-7534

SOURCE Novocure